{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Delmonte A"],"funding":["Bristol Myers Squibb"],"pagination":["538"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12897191"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(3)"],"pubmed_abstract":["<b>Background:</b> Treatment for advanced non-small-cell lung cancer (NSCLC) has evolved substantially over the past decade, necessitating evaluation of real-world treatment patterns and effectiveness before and after the introduction of newer therapies. <b>Methods:</b> This retrospective cohort study included adult patients initiating a non-curative first-line therapy for advanced NSCLC between 2014 and 2021 at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), with follow-up through 2022. Overall survival (OS) and real-world progression-free survival from the start date of the first line of therapy for advanced NSCLC were estimated using Kaplan-Meier methods. <b>Results:</b> Overall, 910 patients were included; at diagnosis, 83% had a de novo diagnosis and 17% had recurrent di"],"journal":["Cancers"],"pubmed_title":["Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study."],"pmcid":["PMC12897191"],"funding_grant_id":["N/A"],"pubmed_authors":["Hindocha P","Delmonte A","Danesi V","Massa I","Maltoni R","Leal C","Glassberg MB","Mella M","Emanuel G","Lay-Flurrie S","Lee A","Roncadori A","Rault C","Gentili N","Oikonomou S","Yuan Y"],"additional_accession":[]},"is_claimable":false,"name":"Real-World Treatment Patterns and Survival in Patients with Advanced Non-Small Cell Lung Cancer: An Italian Retrospective Cohort Study.","description":"<b>Background:</b> Treatment for advanced non-small-cell lung cancer (NSCLC) has evolved substantially over the past decade, necessitating evaluation of real-world treatment patterns and effectiveness before and after the introduction of newer therapies. <b>Methods:</b> This retrospective cohort study included adult patients initiating a non-curative first-line therapy for advanced NSCLC between 2014 and 2021 at the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST), with follow-up through 2022. Overall survival (OS) and real-world progression-free survival from the start date of the first line of therapy for advanced NSCLC were estimated using Kaplan-Meier methods. <b>Results:</b> Overall, 910 patients were included; at diagnosis, 83% had a de novo diagnosis and 17% had recurrent di","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Feb","modification":"2026-07-07T03:16:30.812Z","creation":"2026-07-07T03:08:46.958Z"},"accession":"S-EPMC12897191","cross_references":{"pubmed":["41682008"],"doi":["10.3390/cancers18030538"]}}